|
1
|
Muggia F: Platinum compounds 30 years
after the introduction of cisplatin: implications for the treatment
of ovarian cancer. Gynecol Oncol. 112:275–281. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Armstrong DK: Relapsed ovarian cancer:
challenges and management strategies for a chronic disease.
Oncologist. 7 Suppl 5:20–28. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Markman M, Rothman R, Hakes T, Reichman B,
Hoskins W, Rubin S, Jones W, Almadrones L and Lewis JL Jr:
Second-line platinum therapy in patients with ovarian cancer
previously treated with cisplatin. J Clin Oncol. 9:389–393. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Luvero D, Milani A and Ledermann JA:
Treatment options in recurrent ovarian cancer: latest evidence and
clinical potential. Ther Adv Med Oncol. 6:229–239. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mutch DG, Orlando M, Goss T, Teneriello
MG, Gordon AN, McMeekin SD, Wang Y, Scribner DR Jr, Marciniack M,
Naumann RW and Secord AA: Randomized phase III trial of gemcitabine
compared with pegylated liposomal doxorubicin in patients with
platinum-resistant ovarian cancer. J Clin Oncol. 25:2811–2818.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Monk BJ, Herzog TJ, Kaye SB, Krasner CN,
Vermorken JB, Muggia FM, Pujade-Lauraine E, Lisyanskaya AS, Makhson
AN, Rolski J, et al: Trabectedin plus pegylated liposomal
Doxorubicin in recurrent ovarian cancer. J Clin Oncol.
28:3107–3114. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Meier W, du Bois A, Reuss A, Kuhn W,
Olbricht S, Gropp M, Richter B, Lück HJ, Kimmig R and Pfisterer J:
Topotecan versus treosulfan, an alkylating agent, in patients with
epithelial ovarian cancer and relapse within 12 months following
1st-line platinum/paclitaxel chemotherapy. A prospectively
randomized phase III trial by the Arbeitsgemeinschaft
Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
Gynecol Oncol. 114:199–205. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Buda A, Floriani I, Rossi R, Colombo N,
Torri V, Conte PF, Fossati R, Ravaioli A and Mangioni C: Randomised
controlled trial comparing single agent paclitaxel vs
epidoxorubicin plus paclitaxel in patients with advanced ovarian
cancer in early progression after platinum-based chemotherapy: an
Italian Collaborative Study from the Mario Negri Institute, Milan,
G.O.N.O. (Gruppo Oncologico Nord Ovest) group and I.O.R. (Istituto
Oncologico Romagnolo) group. Br J Cancer. 90:2112–2117.
2004.PubMed/NCBI
|
|
9
|
Gordon AN, Fleagle JT, Guthrie D, Parkin
DE, Gore ME and Lacave AJ: Recurrent epithelial ovarian carcinoma:
a randomized phase III study of pegylated liposomal doxorubicin
versus topotecan. J Clin Oncol. 19:3312–3322. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
ten Bokkel Huinink W, Gore M, Carmichael
J, Gordon A, Malfetano J, Hudson I, Broom C, Scarabelli C, Davidson
N, Spanczynski M, et al: Topotecan versus paclitaxel for the
treatment of recurrent epithelial ovarian cancer. J Clin Oncol.
15:2183–2193. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lortholary A, Largillier R, Weber B,
Gladieff L, Alexandre J, Durando X, Slama B, Dauba J, Paraiso D and
Pujade-Lauraine E: GINECO group France: Weekly paclitaxel as a
single agent or in combination with carboplatin or weekly topotecan
in patients with resistant ovarian cancer: the CARTAXHY randomized
phase II trial from Groupe dInvestigateurs Nationaux pour lEtude
des Cancers Ovariens (GINECO). Ann Oncol. 23:346–352. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
van der Burg ME, De Wit R, van Putten WL,
Logmans A, Kruit WH, Stoter G and Verweij J: Weekly cisplatin and
daily oral etoposide is highly effective in platinum pretreated
ovarian cancer. Br J Cancer. 86:19–25. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sharma R, Graham J, Mitchell H, Brooks A,
Blagden S and Gabra H: Extended weekly dose-dense
paclitaxel/carboplatin is feasible and active in heavily
pre-treated platinum-resistant recurrent ovarian cancer. Br J
Cancer. 100:707–712. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
See HT, Freedman RS, Kudelka AP, Burke TW,
Gershenson DM, Tangjitgamol S and Kavanagh JJ: Retrospective
review: re-treatment of patients with ovarian cancer with
carboplatin after platinum resistance. Int J Gynecol Cancer.
15:209–216. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Matsumoto K, Katsumata N, Yamanaka Y,
Yonemori K, Kohno T, Shimizu C, Andoh M and Fujiwara Y: The safety
and efficacy of the weekly dosing of irinotecan for platinum- and
taxanes-resistant epithelial ovarian cancer. Gynecol Oncol.
100:412–416. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bodurka DC, Levenback C, Wolf JK, Gano J,
Wharton JT, Kavanagh JJ and Gershenson DM: Phase II trial of
irinotecan in patients with metastatic epithelial ovarian cancer or
peritoneal cancer. J Clin Oncol. 21:291–297. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fukuda M, Nishio K, Kanzawa F, Ogasawara
H, Ishida T, Arioka H, Bojanowski K, Oka M and Saijo N: Synergism
between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38,
in human small cell lung cancer cells. Cancer Res. 56:789–793.
1996.PubMed/NCBI
|
|
18
|
Sugiyama T, Yakushiji M, Nishida T,
Ushijima K, Okura N, Kigawa J and Terakawa N: Irinotecan (CPT-11)
combined with cisplatin in patients with refractory or recurrent
ovarian cancer. Cancer Lett. 128:211–218. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kigawa J, Takahashi M, Minagawa Y, Oishi
T, Sugiyama T, Yakushiji M and Terakawa N: Topoisomerase-I activity
and response to second-line chemotherapy consisting of
camptothecin-11 and cisplatin in patients with ovarian cancer. Int
J Cancer. 84:521–524. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Markman M and Bookman MA: Second-line
treatment of ovarian cancer. Oncologist. 5:26–35. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the Eastern Cooperative Oncology Group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rustin GJ, Nelstrop AE, McClean P, Brady
MF, McGuire WP, Hoskins WJ, Mitchell H and Lambert HE: Defining
response of ovarian carcinoma to initial chemotherapy according to
serum CA 125. J Clin Oncol. 14:1545–1551. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
U.S. Department of Health and Human
Services, . Common Terminology Criteria for Adverse Events (CTCAE).
https://evs.
nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdfMarch
17–2017
|
|
25
|
Pujade-Lauraine E, Hilpert F, Weber B,
Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P,
Bamias A, et al: Bevacizumab combined with chemotherapy for
platinum-resistant recurrent ovarian cancer: the AURELIA open-label
randomized phase III trial. J Clin Oncol. 32:1302–1308. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tsubamoto H, Kawaguchi R, Ito K, Shiozaki
T, Takeuchi S, Itani Y, Arakawa A, Tabata T and Toyoda S: Phase II
study of carboplatin and weekly irinotecan combination chemotherapy
in recurrent ovarian cancer: a Kansai clinical oncology group study
(KCOG0330). Anticancer Res. 33:1073–1079. 2013.PubMed/NCBI
|
|
27
|
Misawa T, Kikkawa F, Maeda O, Obata NH,
Higashide K, Suganuma N and Tomoda Y: Establishment and
characterization of acquired resistance to platinum anticancer
drugs in human ovarian carcinoma cells. Jpn J Cancer Res. 86:88–94.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Takano M, Kato M, Yoshikawa T, Sasaki N,
Hirata J, Furuya K, Takahashi M, Yokota H, Kino N, Horie K, et al:
Clinical significance of UDP-glucuronosyltransferase 1A1*6 for
toxicities of combination chemotherapy with irinotecan and
cisplatin in gynecologic cancers: a prospective multi-institutional
study. Oncology. 76:315–321. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ichikawa W, Uehara K, Minamimura K, Tanaka
C, Takii Y, Miyauchi H, Sadahiro S, Fujita K, Moriwaki T, Nakamura
M, et al: An internally and externally validated nomogram for
predicting the risk of irinotecan-induced severe neutropenia in
advanced colorectal cancer patients. Br J Cancer. 112:1709–1716.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cannistra SA, Matulonis UA, Penson RT,
Hambleton J, Dupont J, Mackey H, Douglas J, Burger RA, Armstrong D,
Wenham R and McGuire W: Phase II study of bevacizumab in patients
with platinum-resistant ovarian cancer or peritoneal serous cancer.
J Clin Oncol. 25:5180–5186. 2007. View Article : Google Scholar : PubMed/NCBI
|
